PureIMS has announced that personalized medicine company Fagron has acquired exclusive rights to distribute PureIMS’s Cyclops dry powder inhaler with compounded inhalation powders in the Netherlands. The Cyclops DPIs, which are pre-filled with drug, will be dispensed by compounding pharmacy Infinity Pharma.
According to the announcement, the deal includes “PureIMS’s compounded preparations, such as an inhaled antibiotic for the treatment of pulmonary Pseudomonas aeruginosa infections caused by cystic fibrosis.” The PureIMS web site lists a compounded colistin product delivered via the Cyclops inhaler that has been available to Dutch patients under a named patient program since 2015 among its pipeline products.
PureIMS CEO Jaap Wieling commented, “The collaboration is an important step forward for our company. We know that many patients can benefit from using Cyclops-based inhaled medication. It is therefore fantastic that we can now serve patients across the Netherlands with excellent support, thanks to Fagron and Infinity Pharma. At the same time, we work towards marketing approval of our products within the EU, the United States, and beyond.”
Fagron Product & Innovation Manager Sjoerd van Olffen said, “Inhalation is a very patient-friendly route of drug delivery. Because the patient is central to everything Fagron does, innovations like Cyclops fit well within our product line, and we are very pleased with this addition.”
In January 2024, PureIMS that it was planning an abbreviated submission for its lead product, Levodopa Cyclops for the treatment of OFF episodes in Parkinson’s disease. The company’s pipeline also includes Cyclops versions of epinephrine, tobramycin, and amikacin.
Read the PureIMS press release.
